Invention Grant
- Patent Title: Macrocyclic compounds that inhibit MCL-1 protein
-
Application No.: US16642441Application Date: 2018-08-27
-
Publication No.: US11279712B2Publication Date: 2022-03-22
- Inventor: Sean P. Brown , Yunxiao Li , Paul E. Harrington , Brian Alan Lanman , Jonathan D. Low , Ana Elena Minatti , Vu Van Ma , Kexue Li
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agent Bernard P. Friedrichsen
- International Application: PCT/US2018/048058 WO 20180827
- International Announcement: WO2019/046150 WO 20190307
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07D513/08 ; C07D519/00 ; A61P35/00 ; A61K31/496 ; A61K31/5377 ; A61K31/7068

Abstract:
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Public/Granted literature
- US20200247821A1 MACROCYCLIC COMPOUNDS THAT INHIBIT MCL-1 PROTEIN Public/Granted day:2020-08-06
Information query